Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2003 1
2005 1
2006 1
2008 2
2012 2
2014 1
2015 2
2016 1
2017 2
2018 2
2019 2
2020 2
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Malignant Salivary Gland Neoplasm"
Page 1
Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
Ueda Y, Okano S, Enokida T, Fujisawa T, Ito K, Sato M, Tanaka H, Wada A, Tahara M. Ueda Y, et al. Oral Oncol. 2022 Jul;130:105932. doi: 10.1016/j.oraloncology.2022.105932. Epub 2022 May 27. Oral Oncol. 2022. PMID: 35636078
The main primary site included the sinonasal cavity (n = 18), salivary gland (n = 15), and nasopharynx (n = 13). Three (6.0%) patients achieved a complete response and 5 (10.0%) a partial response, giving an overall response rate (ORR) of 16.6%. Median time-to-treat …
The main primary site included the sinonasal cavity (n = 18), salivary gland (n = 15), and nasopharynx (n = 13). Three (6.0%) …
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Diamond JR, Boni V, Lim E, Nowakowski G, Cordoba R, Morillo D, Valencia R, Genvresse I, Merz C, Boix O, Frigault MM, Greer JM, Hamdy AM, Huang X, Izumi R, Wong H, Moreno V. Diamond JR, et al. Clin Cancer Res. 2022 Apr 1;28(7):1285-1293. doi: 10.1158/1078-0432.CCR-21-3617. Clin Cancer Res. 2022. PMID: 35046056 Clinical Trial.
Seven of 30 patients with solid tumors had stable disease (including 9.5 and 16.8 months in individual patients with pancreatic cancer and salivary gland cancer, respectively), and 2 of 7 patients with high-grade B-cell lymphoma with MYC and BCL2/BCL6 translocations …
Seven of 30 patients with solid tumors had stable disease (including 9.5 and 16.8 months in individual patients with pancreatic cancer and …
Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.
Zheng S, Li H, Lin Y, Xie Y, Yin Z, Ge W, Yu T. Zheng S, et al. Anticancer Drugs. 2022 Jan 1;33(1):e548-e554. doi: 10.1097/CAD.0000000000001171. Anticancer Drugs. 2022. PMID: 34321419 Free PMC article.
Adenoid cystic carcinoma (ACC) is a rare salivary glands tumor and often displays aggressive behavior with frequent relapse and metastasis. ...This study presented the first case of perianal ACC with multiple pulmonary metastases and particular BCOR mutations, who presente …
Adenoid cystic carcinoma (ACC) is a rare salivary glands tumor and often displays aggressive behavior with frequent relapse and metas …
Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma.
Parag-Sharma K, Tasoulas J, Musicant AM, do Nascimento-Filho CHV, Zhu Z, Twomey C, Liu P, Castilho RM, Amelio AL. Parag-Sharma K, et al. Oral Oncol. 2021 Apr;115:105166. doi: 10.1016/j.oraloncology.2020.105166. Epub 2021 Feb 11. Oral Oncol. 2021. PMID: 33581505 Free PMC article.
OBJECTIVES: Mucoepidermoid carcinoma (MEC) is the most common type of salivary gland malignancy. Advanced or high-grade MECs are refractory to chemotherapy, often leading to tumor recurrence/metastasis and abysmal ~35% 5-year survival. ...Future studies are n …
OBJECTIVES: Mucoepidermoid carcinoma (MEC) is the most common type of salivary gland malignancy. Advanced or high-grade MECs a …
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.
Papadopoulos KP, Lakhani N, Falchook GS, Riley G, Baeck J, Brown KS, Gordon G, Le L, Wang JS. Papadopoulos KP, et al. Cancer Immunol Immunother. 2021 Mar;70(3):763-772. doi: 10.1007/s00262-020-02730-5. Epub 2020 Sep 28. Cancer Immunol Immunother. 2021. PMID: 32989552 Free PMC article. Clinical Trial.
Secondary objectives included evaluation of the pharmacokinetics (PK) of JTX-4014, anti-drug antibodies (ADA) against JTX-4014, and clinical activity. RESULTS: JTX-4014 was well tolerated and no new safety signals were identified as compared with other PD-1is. ...CONCLUSIO …
Secondary objectives included evaluation of the pharmacokinetics (PK) of JTX-4014, anti-drug antibodies (ADA) against JTX-4014, and clini …
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers.
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM. Subbiah V, et al. Cancer Discov. 2020 May;10(5):657-663. doi: 10.1158/2159-8290.CD-19-1265. Epub 2020 Feb 6. Cancer Discov. 2020. PMID: 32029534 Free PMC article.
Responses were observed in 13 unique cancer types, including historically treatment-refractory tumor types such as cholangiocarcinoma, sarcoma, glioma, neuroendocrine carcinoma, and salivary gland carcinomas. Collectively, these data demonstrate that single-a …
Responses were observed in 13 unique cancer types, including historically treatment-refractory tumor types such as cholangiocarcinoma …
New agents in the treatment for malignancies of the salivary and thyroid glands.
Mehra R, Cohen RB. Mehra R, et al. Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi. doi: 10.1016/j.hoc.2008.08.010. Hematol Oncol Clin North Am. 2008. PMID: 19010274 Free PMC article. Review.
The treatment of relatively rare malignancies, such as those of the salivary glands and iodine refractory thyroid cancer, has been invigorated by the development of novel molecular targeting agents. ...This article briefly summarizes the epidemiology and pathogenesi …
The treatment of relatively rare malignancies, such as those of the salivary glands and iodine refractory thyroid cancer, has …
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
Martin N, Isambert N, Gomez-Roca C, Goeldner RG, Zanetta S, Sadrolhefazi B, de Mont-Serrat H, Campone M, Delord JP. Martin N, et al. Cancer Chemother Pharmacol. 2018 Dec;82(6):979-986. doi: 10.1007/s00280-018-3689-2. Epub 2018 Oct 22. Cancer Chemother Pharmacol. 2018. PMID: 30350178 Free PMC article. Clinical Trial.
BACKGROUND: Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metasta …
BACKGROUND: Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occur …
Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial.
Hoover AC, Milhem MM, Anderson CM, Sun W, Smith BJ, Hoffman HT, Buatti JM. Hoover AC, et al. Head Neck. 2015 May;37(5):722-6. doi: 10.1002/hed.23664. Epub 2014 Jun 18. Head Neck. 2015. PMID: 24596143 Free PMC article. Clinical Trial.
BACKGROUND: Adenoid cystic carcinomas (ACCs) are malignant salivary gland tumors noteworthy for high rates of late failure with limited salvage therapy options. ...CONCLUSION: NFV monotherapy does not result in a meaningful improvement in clinical outc …
BACKGROUND: Adenoid cystic carcinomas (ACCs) are malignant salivary gland tumors noteworthy for high rates of late fail …
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW. Hotte SJ, et al. Ann Oncol. 2006 Feb;17(2):334-40. doi: 10.1093/annonc/mdj076. Epub 2005 Nov 10. Ann Oncol. 2006. PMID: 16284058 Free article. Clinical Trial.
This phase I study was designed to determine the maximal tolerated dose (MTD), recommended phase 2 dose (RPTD), toxicity profile, pharmacokinetics and antitumor activity of T and UCN-01 in patients with refractory solid tumors. DESIGN: Both agents were administered every 2 …
This phase I study was designed to determine the maximal tolerated dose (MTD), recommended phase 2 dose (RPTD), toxicity profile, pharmacoki …
20 results